Related Experiment Videos
Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
The Patient Who Could Not Die.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026